Credit Suisse’s iShares Biotechnology ETF IBB Stock Holding History

Credit Suisse’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-76,600	Closed	-$11.7M	–	3938
2021 Q4	$11.7M	Buy	76,600 +5,900	+8%	+$913K	0.01%	1386
2021 Q3	$11.4M	Sell	70,700 -97,200	-58%	-$16.4M	0.01%	1445
2021 Q2	$27.5M	Buy	167,900 +17,900	+12%	+$2.76M	0.01%	987
2021 Q1	$22.6M	Sell	150,000 -26,600	-15%	-$4.22M	0.01%	1101
2020 Q4	$26.8M	Hold	176,600	–	–	0.01%	1012
2020 Q3	$23.9M	Hold	176,600	–	–	0.01%	940
2020 Q2	$24.1M	Hold	176,600	–	–	0.02%	853
2020 Q1	$19M	Sell	176,600 -60,900	-26%	-$7.01M	0.02%	868
2019 Q4	$28.6M	Hold	237,500	–	–	0.02%	835
2019 Q3	$23.6M	Buy	237,500 +100,000	+73%	+$10.5M	0.02%	813
2019 Q2	$15M	Buy	137,500 +62,000	+82%	+$6.59M	0.01%	1082
2019 Q1	$8.44M	Buy	+75,500	New	+$8.28M	0.01%	1339
2016 Q2	–	Sell	-14,400	Closed	-$1.25M	–	4261
2016 Q1	$1.25M	Buy	+14,400	New	+$1.29M	﹤0.01%	2563

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Credit Suisse's IBB Position: Q1 2024 in Review

Credit Suisse reduced its iShares Biotechnology ETF (IBB) stake by 9% in Q1 2024, selling an estimated $71.8K and leaving 5,307 shares worth $728K. The position accounts for ﹤0.01% of the portfolio, ranked #2455.

Credit Suisse first reported a position in IBB in Q2 2013 and has held it in 44 quarters since. The position peaked at $342M in Q3 2015. 899 funds tracked by Wall St. Rank hold IBB as of Q1 2024.

Credit Suisse held 5,307 shares of iShares Biotechnology ETF worth $728K as of Q1 2024.
Credit Suisse sold 526 iShares Biotechnology ETF shares in Q1 2024, an estimated $71.8K.
iShares Biotechnology ETF made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2455 holding.
Credit Suisse first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 44 quarters since.
Credit Suisse's iShares Biotechnology ETF position peaked at $342M in Q3 2015.
899 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.